Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells
April 18 2017 - 8:30AM
Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an
oncology-focused, clinical stage biotechnology company, today
announces the Japanese Patent Office has granted a method of use
patent for two of the company’s phospholipid drug conjugates
(PDCs), CLR 131, the company’s lead compound, and CLR 125, each in
combination with radiation and/or other therapies to treat cancer
stem cells. CLR 125 is a radiotherapeutic isotope conjugated
to the company’s proprietary PDC delivery platform, which may
be uniquely suited to treat select cancer and micro-metastatic
disease.
The recently issued method of use patent, JP 6092624 includes
seven claims for CLR 131 and CLR 125 in treating cancer stem cells
in a variety of cancers, including brain (glioma), kidney,
colorectal, ovarian, prostate, breast, pancreatic and skin cancers,
as well as squamous cell carcinoma. The claims further
specify the combination of either CLR 131 or CLR 125 with external
beam radiation as part of combination therapy with chemotherapy,
tumor resection, ablative therapy, or local physical treatment on
the basis of cold (cryo), heat (thermal), radiofrequency, and
microwave treatments. The patent allows intellectual property
protection in Japan through June 11, 2030. “This method of use
patent strengthens our intellectual property portfolio in a
strategic market and further validates the clinical utility of our
PDC compounds on both cancer cells and cancer stem cells,” said Jim
Caruso, president and CEO of Cellectar. “We continue to be
encouraged by the progress in the clinical development of our lead
compound CLR 131, and this expanded patent protection further
supports our belief in its utility in blood cancers, for which we
are currently conducting both a Phase I and II trial, as well as
its potential in other cancer types.” About CLR
131 CLR 131 is an investigational compound under
development for a range of hematologic malignancies. It is
currently being evaluated as a single-dose treatment in a Phase I
clinical trial in patients with relapsed or refractory (R/R)
multiple myeloma as well as in a Phase II clinical trial for R/R MM
and select R/R lymphomas with either a one- or two-dose treatment.
Based upon preclinical and interim Phase I study data, treatment
with CLR 131 provides a novel approach to treating hematological
diseases and may provide patients with therapeutic benefits,
including overall survival, an improvement in progression-free
survival, surrogate efficacy marker response rate, and overall
quality of life. CLR 131 utilizes the company's patented PDC tumor
targeting delivery platform to deliver a cytotoxic radioisotope,
iodine-131, directly to tumor cells. The FDA has granted Cellectar
an orphan drug designation for CLR 131 in the treatment of multiple
myeloma.
About Phospholipid Drug Conjugates
(PDCs)Cellectar’s product candidates are built upon its
patented cancer cell-targeting delivery and retention platform of
optimized phospholipid ether-drug conjugates (PDCs). The
company deliberately designed its phospholipid ether (PLE) carrier
platform to be coupled with a variety of payloads to facilitate
both therapeutic and diagnostic applications. The basis for
selective tumor targeting of our PDC compounds lies in the
differences between the plasma membranes of cancer cells compared
to those of normal cells. Cancer cell membranes are highly
enriched in lipid rafts, which are glycolipoprotein microdomains of
the plasma membrane of cells that contain high concentrations of
cholesterol and sphingolipids, and serve to organize cell surface
and intracellular signaling molecules. PDCs have been tested in
more than 80 different xenograft models of cancer.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have
demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product
candidates for cancer therapy and cancer diagnostic imaging.
The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a
cytotoxic radioisotope, as its payload. CLR 131 is currently
being evaluated under an orphan drug designated Phase I clinical
study in patients with relapsed or refractory multiple
myeloma. In addition, the company has initiated a Phase II
clinical study to assess efficacy in a range of B-cell
malignancies. The company is also developing PDCs for
targeted delivery of chemotherapeutics such as paclitaxel (CLR
1602-PTX), a preclinical stage product candidate, and plans to
expand its PDC chemotherapeutic pipeline through both in-house and
collaborative R&D efforts. For more information please
visit www.cellectar.com.
This news release contains forward-looking statements. You
can identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current
beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk.
Factors that might cause such a material difference include, among
others, uncertainties related to the ability to raise additional
capital, uncertainties related to the ability to attract and retain
partners for our technologies, the identification of lead
compounds, the successful preclinical development thereof, the
completion of clinical trials, the FDA review process and other
government regulation, our pharmaceutical collaborators' ability to
successfully develop and commercialize drug candidates, competition
from other pharmaceutical companies, product pricing and
third-party reimbursement. A complete description of risks
and uncertainties related to our business is contained in our
periodic reports filed with the Securities and Exchange Commission
including our Form 10-K for the year ended December 31,
2016 These forward-looking statements are made only as of the
date hereof, and we disclaim any obligation to update any such
forward-looking statements.
CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From May 2023 to May 2024